Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering
Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform
Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
